Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 972
Publisher
MDPI AG
Online
2020-04-15
DOI
10.3390/cancers12040972
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NQO1-dependent, tumor-selective radiosensitization of non-small cell lung cancers
- (2019) Edward A. Motea et al. CLINICAL CANCER RESEARCH
- Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation
- (2019) Julia O’Sullivan et al. Nature Communications
- New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
- (2019) Daniela Criscuolo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
- (2019) Nisha Pillay et al. CANCER CELL
- H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism
- (2019) Mei-Kuang Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
- (2019) Zhiwang Song et al. Cell Death & Disease
- The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
- (2019) Aubrey L. Miller et al. EBioMedicine
- Defining and Modulating ‘BRCAness’
- (2019) Andrea K. Byrum et al. TRENDS IN CELL BIOLOGY
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
- (2019) Victor Quereda et al. CANCER CELL
- ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers
- (2019) Lesley B. Conrad et al. MOLECULAR CANCER THERAPEUTICS
- Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
- (2019) Shuai Wang et al. Nature Chemical Biology
- Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
- (2019) Chia-Sui Weng et al. Cancer Management and Research
- NAD metabolism: Implications in aging and longevity
- (2018) Keisuke Yaku et al. AGEING RESEARCH REVIEWS
- PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
- (2018) Linglong Yin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer
- (2018) Kuojun Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
- (2018) Yazhuo Zhang et al. Molecular Cancer
- PARP Inhibitors in Ovarian Cancer
- (2018) Gloria Mittica et al. Recent Patents on Anti-Cancer Drug Discovery
- MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models
- (2018) Francesca Vena et al. Oncotarget
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- Single-Strand Break End Resection in Genome Integrity: Mechanism and Regulation by APE2
- (2018) Md. Hossain et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis
- (2018) J. Patrick Murphy et al. Cell Reports
- EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma
- (2018) Qiongzhu Dong et al. CANCER RESEARCH
- Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib
- (2018) Qian Zhong et al. GYNECOLOGIC ONCOLOGY
- Oncogenic activity of poly (ADP-ribose) glycohydrolase
- (2018) Maud Marques et al. ONCOGENE
- CCDC6: the identity of a protein known to be partner in fusion
- (2017) Aniello Cerrato et al. INTERNATIONAL JOURNAL OF CANCER
- The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism
- (2017) Molly A. Silvers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer
- (2017) Muhammad Shaalan Beg et al. JOURNAL OF SURGICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
- (2017) Tamara B. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
- (2017) Genshi Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- Olaparib Keeps Hereditary Breast Tumors in Check
- (2017) Cancer Discovery
- Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
- (2017) Seokuee Kim et al. Drug Design Development and Therapy
- Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer
- (2017) Jair Machado Espindola-Netto et al. Oncotarget
- NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis
- (2017) Antonio Lucena-Cacace et al. Oncotarget
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
- (2017) Tarra Evans et al. Therapeutic Advances in Medical Oncology
- Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
- (2016) Xiumei Huang et al. CANCER CELL
- Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer
- (2016) Huai-Qiang Ju et al. CANCER LETTERS
- Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
- (2016) Susan M. Domchek et al. GYNECOLOGIC ONCOLOGY
- AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers
- (2016) Kavitha Balaji et al. MOLECULAR CANCER RESEARCH
- Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
- (2016) O. Abu Aboud et al. MOLECULAR CANCER THERAPEUTICS
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity
- (2016) Jin-Chong Xu et al. Science Translational Medicine
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- TNF and ROS Crosstalk in Inflammation
- (2016) Heiko Blaser et al. TRENDS IN CELL BIOLOGY
- Genomic landscape of DNA repair genes in cancer
- (2016) Young Kwang Chae et al. Oncotarget
- Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma
- (2016) Simone M. Goldinger et al. JAMA Dermatology
- Functions of PARylation in DNA Damage Repair Pathways
- (2016) Huiting Wei et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics
- (2015) Michael O. Hottiger Annual Review of Biochemistry
- High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma
- (2015) Xuelian Cui et al. BMC CANCER
- NQO1 protein expression predicts poor prognosis of non-small cell lung cancers
- (2015) Zhenling Li et al. BMC CANCER
- PARP inhibitors in the management of breast cancer: current data and future prospects
- (2015) Luca Livraghi et al. BMC Medicine
- Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage
- (2015) W. Wu et al. CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer
- (2015) YANYAN ZHU et al. ONCOLOGY REPORTS
- NAD+ in aging, metabolism, and neurodegeneration
- (2015) E. Verdin SCIENCE
- Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway?
- (2015) Agnel Sfeir et al. TRENDS IN BIOCHEMICAL SCIENCES
- NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone
- (2015) Z Moore et al. Cell Death & Disease
- PCAT-1 , a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer
- (2014) John R. Prensner et al. CANCER RESEARCH
- On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
- (2014) I. Gehrke et al. CLINICAL CANCER RESEARCH
- Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma
- (2014) Lijuan Lin et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death
- (2014) Christopher Del Nagro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical implications of high NQO1 expression in breast cancers
- (2014) Yang Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- TGFβ Induces “BRCAness” and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes
- (2014) Liang Liu et al. MOLECULAR CANCER RESEARCH
- NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer
- (2014) XUELIAN CUI et al. ONCOLOGY REPORTS
- Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis
- (2014) S. A. Andrabi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NAD+ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study
- (2014) Shuraila F. Zerp et al. RADIOTHERAPY AND ONCOLOGY
- The Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor PJ34 Reduces Pulmonary Ischemia-Reperfusion Injury in Rats
- (2014) Go Hatachi et al. TRANSPLANTATION
- Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage
- (2013) Ludovic Deriano et al. Annual Review of Genetics
- The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling
- (2013) Laurent Mouchiroud et al. CELL
- Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
- (2013) Julio Morales et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Push back to respond better: regulatory inhibition of the DNA double-strand break response
- (2013) Stephanie Panier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways
- (2013) H Shirai et al. Cell Death & Disease
- Resistance to PARP-Inhibitors in Cancer Therapy
- (2013) Alicia Montoni et al. Frontiers in Pharmacology
- Selective Small Molecule Inhibition of Poly(ADP-Ribose) Glycohydrolase (PARG)
- (2012) Kristin E. Finch et al. ACS Chemical Biology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- RNA Interference of PARG Could Inhibit the Metastatic Potency of Colon Carcinoma Cells via PI3-Kinase/Akt Pathway
- (2012) Qiaozhuan Li et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53- and Nicotinic Acid Phosphoribosyltransferase1 (NAPRT1)-dependent Manner
- (2012) David Cerna et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+Biosynthesis, in Human Cancer Cells
- (2012) Bo Tan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ADP-ribosylhydrolase 3 (ARH3), Not Poly(ADP-ribose) Glycohydrolase (PARG) Isoforms, Is Responsible for Degradation of Mitochondrial Matrix-associated Poly(ADP-ribose)
- (2012) Marc Niere et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
- (2011) Siwanon Jirawatnotai et al. NATURE
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer
- (2011) Jill Kolesar ONCOLOGY REPORTS
- Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1-Dependent Cell Death (Parthanatos)
- (2011) Y. Wang et al. Science Signaling
- Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
- (2011) D. A. Chan et al. Science Translational Medicine
- The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
- (2010) Michael R. Lieber Annual Review of Biochemistry
- Identification of a Regulatory Segment of Poly(ADP-ribose) Glycohydrolase
- (2010) Davide Botta et al. BIOCHEMISTRY
- Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation
- (2010) Y. Dong et al. CANCER RESEARCH
- -Lapachone Micellar Nanotherapeutics for Non-Small Cell Lung Cancer Therapy
- (2010) E. Blanco et al. CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- Efficacy of Combining GMX1777 with Radiation Therapy for Human Head and Neck Carcinoma
- (2010) H. Kato et al. CLINICAL CANCER RESEARCH
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response
- (2010) B Wang et al. ONCOGENE
- Postischemic poly (ADP-ribose) polymerase (PARP) inhibition reduces ischemia reperfusion injury in a hind-limb ischemia model
- (2010) Robert S. Crawford et al. SURGERY
- Toward a unified nomenclature for mammalian ADP-ribosyltransferases
- (2010) Michael O. Hottiger et al. TRENDS IN BIOCHEMICAL SCIENCES
- Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
- (2009) Anne von Heideman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Poly(ADP-ribose) Glycohydrolase Deficiency Sensitizes Mouse ES Cells to DNA Damaging Agents
- (2009) H. Fujihara et al. CURRENT CANCER DRUG TARGETS
- Parthanatos, a messenger of death
- (2009) Karen Kate David Frontiers in Bioscience-Landmark
- The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors
- (2009) M. Watson et al. MOLECULAR AND CELLULAR BIOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer agent CHS-828 inhibits cellular synthesis of NAD
- (2008) Uffe Høgh Olesen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Mono-galloyl glucose derivatives are potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP-1-dependent cell death
- (2008) L Formentini et al. BRITISH JOURNAL OF PHARMACOLOGY
- Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury
- (2007) R Mota et al. BRITISH JOURNAL OF PHARMACOLOGY
- The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases
- (2007) Paul et al. Frontiers in Bioscience-Landmark
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started